Background: Whether diagnostic route (e.g. emergency presentation) is associated with cancer care experience independently of tumour stage is unknown. Methods: We analysed data on 18 590 patients with breast, prostate, colon, lung, and rectal cancers who responded to the 2014 English Cancer Patient Experience Survey, linked to cancer registration data on diagnostic route and tumour stage at diagnosis. We estimated odds ratios (OR) of reporting a negative experience of overall cancer care by tumour stage and diagnostic route (crude and adjusted for patient characteristic and cancer site variables) and examined their interactions with cancer site. Results: After adjustment, the likelihood of reporting a negative experience was highest for emergency presenters and lowest for screening-detected patients with breast, colon, and rectal cancers (OR versus two-weekwait 1.51, 95% confidence interval [CI] 1.24-1.83; 0.88, 95% CI 0.75-1.03, respectively). Patients with the most advanced stage were more likely to report a negative experience (OR stage IV versus I 1.37, 95% CI 1.15-1.62) with little confounding between stage and route, and no evidence for cancer-stage or cancer-route interactions. Conclusions: Though the extent of disease is strongly associated with ratings of overall cancer care, diagnostic route (particularly emergency presentation or screening detection) exerts important independent effects.
Introduction
A positive experience of cancer care is increasingly understood to represent a key aspect of high quality cancer services. [1, 2] In several countries, this realisation has led to initiatives supporting the measurement of the experience of cancer patients through patient surveys. [3] [4] [5] [6] [7] [8] While those surveys chiefly focus on the public reporting of hospital scores of patients' satisfaction with cancer care, understanding person-level variation is also important.
Women, younger and very old, and ethnic minority patients report worse cancer care experiences. [9, 10] Additionally, certain cancer sites, particularly those with generally poor survival such as lung cancer, are associated with worse than average experiences (and vice versa for cancer sites with good prognosis, such as breast cancer) [9] . In spite of evidence on socio-demographic and cancer site variation in patient experience, there is little appreciation of how disease factors (including tumour stage at diagnosis) are associated with the experience of cancer care. Such influences are indeed plausible, as demonstrated by previous research showing that patients with different types of cancer reported variable experiences even when treated by the same specialty. [11] Diagnostic route [12, 13] , denoting whether the cancer was diagnosed thorough screening detection, or in an elective or emergency care context, has prognostic implications and may also be important for patient experience. Previously examined associations between diagnostic route and cancer care experience were confined to a single cancer (colorectal) and did not account for potential confounding of the examined associations by tumour stage. [14] We therefore aimed to examine whether in patients with common cancers diagnostic route and tumour stage at diagnosis are independently associated with differential evaluation of cancer care experience.
Methods

Data source
We analysed anonymous data from responders to the 2014 English Cancer Patient Experience Survey (CPES), [3] a postal survey of patients aged 16 years and older who were treated for cancer in English National Health Service (NHS) hospitals during the period September-November 2013. The survey was commissioned by NHS England and provided by Quality Health. Following vital status checks, patients were sent a survey questionnaire by post, with up to two reminders for non-responders. Of the 109 760 surveyed patients, 70 141 responded to the survey (response rate = 64%).
Variables
Outcome. We examined responses to the survey question 70: 'Overall, how would you rate your care?', with five possible informative response categories of 'Excellent / Very good / Good / Fair / Poor'. Responses were dichotomised into two broad categories defined as 'positive' Excellent -Very good) and 'negative' (all other response options) ratings, consistent with how this item is reported publicly. [3] Main exposures. The exposures of primary interest were tumour stage at diagnosis and diagnostic route. Information on these two variables was provided by linkage of the 2014 CPES responders' sample to the cancer registration data, carried out by the Public Health England National Cancer Registration and Analysis Services (PHE NCRAS). [15] [16] [17] Data were linked deterministically on the basis of matching NHS patient numbers and relevant International Classification of Disease (ICD)-10 diagnosis codes [18] , taking into account relevant diagnosis time windows. [16] Diagnostic route refers to care pathways leading to the diagnosis of cancer. It is derived algorithmically (by PHE NCRAS) linking together cancer registration, Hospital Episode Statistics, screening, and Cancer Waiting Times data. [12] We used a five-category definition of diagnostic route, comprising the following [12, 14] .
• Emergency presentation: cancer diagnosis soon after any of emergency hospital admission, attendance at the Accident and Emergency department, emergency GP referral or emergency between-hospital transfer;
• Urgent primary to secondary care referral for suspected cancer (also known as 'two-week-wait' referral): patients are to be assessed by specialist hospital services within two weeks;
• Elective primary to secondary care referral: primary care referral other than through the two-week-wait route where patients attend routine (non-urgent) out-patient appointments;
• Screening detection: breast, or colon/rectal cancer diagnosis following participation in NHS screening programmes.
• Other routes: not described above.
Tumour stage at diagnosis is based on the relevant field of the English cancer registration system and is assigned by registrars based on information on clinical, pathology, and imaging records. For the analysis, tumour stage was defined as stages I (least advanced) to IV (most advanced) 13 . A small number of stage-0 patients were also treated as having stage-I tumours.
Other covariates. We also considered the responders' age group (<55, 55-64, 65-74, 75+ years old), sex, and deprivation status (quintiles 1 to 5, from least to most deprived), based on cancer registration data. For deprivation status, the population-weighted quintile of the income domain from the Indices of Multiple Deprivation (IMD) 2015 [19] was derived by assigning each patient to the deprivation category of their Lower Super Output Areas using the postcode of residence at the time of diagnosis. Patients' cancer diagnoses were recorded using the ICD-10 diagnosis codes [18] based on cancer registration data.
Sample derivation
We a priori restricted our analyses to survey responders who indicated that they had been treated for cancer in the last year (using responses to question 76: 'How long is it since you were first treated for this cancer?'), and patients with the five most common sites (breast, prostate, lung, colon, and rectal cancer). In the context of relatively high data completeness, we excluded from subsequent analyses responders with missing information on the outcome (response to question 70), tumour stage, diagnostic route, and patient characteristic variables.
Statistical analysis
We first calculated the crude proportions of reporting a negative experience of overall cancer care by diagnostic route and tumour stage. Subsequently, we used logistic regression models to examine the associations of overall cancer care rating with diagnostic route and tumour stage. We obtained (i) the unadjusted odds ratios (OR) of reporting a negative experience for diagnostic route or tumour stage; (ii) the adjusted ORs for either diagnostic route or tumour stage (in different models), conditional on patient characteristic and cancer site variables; and (iii) the adjusted ORs for both diagnostic route and tumour stage in the same model, conditional on patient characteristic and cancer site variables. In the final multivariable logistic regression model with both diagnostic route and tumour stage, we further examined pairwise interactions of each of these two variables with cancer site. All analyses were conducted in Stata v15.2 [20] .
Results
In total, there were 21 934 patients with a diagnosis of one of the five studied cancers (breast, prostate, lung, colon, rectal) who had been treated in the last year. After exclusions due to missing data, the analysis sample comprised 18 590 responders (Fig. 1) . Across cancer sites, 
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Cancer Epidemiology 61 (2019) [70] [71] [72] [73] [74] [75] [76] [77] [78] there were associations between tumour stage and diagnostic route, with stage IV being generally more frequent among emergency presenters and stage I among screening-detected patients (with breast, colon, and rectal cancer) (Appendix 1). There was large variation in both tumour stage and diagnostic route by patient characteristic variables and cancer site (Appendix 2). The percentage of patients reporting a negative experience of overall cancer care was 10% (Table 1) . Table 1 and Fig. 2 present the frequencies and percentages, as well as crude and adjusted odds ratios of a negative rating of overall cancer care by tumour stage and diagnostic route, as well as other patient characteristic and cancer site variables.
Overall, the younger and the very old patients, those living in more deprived areas, and those with prostate cancer were more likely to report a negative experience of cancer care (Table 1) .
In fully adjusted analysis (including patient characteristic, cancer site, tumour stage, and diagnostic route variables) younger patients (OR <55 vs 65-74 years old 1.58, 95% confidence interval [CI] 1.37-1.83); women (OR female vs male 1.51, 95% CI 1.29-1.76); and those living in more deprived areas (OR deprivation quintile 5 vs 1 1.50, 95% CI 1.28-1.77) had a higher likelihood of reporting a negative experience of overall care. There was some variation by cancer site, with breast cancer having the lowest and prostate cancer the highest likelihood of reporting a negative rating of overall care (Table 1, Fig. 2 ). Comparing the results from unadjusted and adjusted analyses we observed a similar overall pattern of variation, though this comparison indicated a substantial amount of confounding between sex and cancer site.
In the same adjusted model, tumour stage and diagnostic route were (independently of each other) associated with satisfaction ratings of overall cancer care. Patients diagnosed with stage IV tumours were most likely to report an overall negative experience of their care (OR stage IV vs stage I 1.37, 95% CI 1.15-1.62), as were those diagnosed through an emergency presentation (OR emergency vs two-week-wait referral 1.51, 95% CI 1.24-1.83). Patients diagnosed through an elective (i.e. not two-week-wait) referral were also more likely to report a negative experience than those diagnosed through screening or twoweek-wait referral (OR elective vs two-week-wait referral 1.24, 95% CI 1.09-1.43). Screening detected patients (with breast, colon, and rectal cancers) had a lower risk of reporting a negative experience of their care than those diagnosed via other routes (OR screening vs two-weekwait 0.88, 95% CI 0.75-1.03). Comparing the fully adjusted model to the one which excludes diagnostic route shows that there was only minor attenuation of the effect associated with tumour stage at diagnosis when adjusting for diagnostic route (e.g. OR for stage IV vs I decreased from 1.44 to 1.37). Similarly, there was only a small attenuation in the effect of diagnostic route when adjusting for stage (e.g. OR for emergency presentation vs two-week-wait referral decreased from 1.60 to 1.51).
In additional analyses, there was no evidence for pairwise interactions between cancer site and either tumour stage (p-value = 0.117), or diagnostic route (p-value = 0.628) (Appendix 3). In other words, there was no evidence that the associations between ratings of overall cancer care and either tumour stage or diagnostic route varied between patients with the studied cancers.
Discussion
Summary of findings
Among patients with breast, prostate, lung, colon, and rectal cancers, emergency presentation, elective referral route and stage-IV tumours at diagnosis were associated with a higher likelihood of reporting a negative experience of overall care, after adjusting for other patient characteristic and cancer site variables. Although there was evidence that some of the effect of stage at diagnosis operated through diagnostic route and vice-versa, the magnitude of this mediation was small and the two variables are associated with ratings of overall care independently of each other.
Strengths and limitations
Our analyses were based on data from a large nationwide sample of cancer patients with high response rate -representing the largest available collection of patient experience data in cancer patients. Information on tumour stage and diagnostic route was provided by linkage to population-based datasets, which enabled us to examine their associations with overall cancer care experience ratings. We were able to adjust our principal findings (with regard to associations with tumour stage and diagnostic route) for a range of patient factors, including age group, sex, deprivation, and cancer site, which are known to be associated with patient experience. [9, 21, 22] The overall completeness of the outcome and exposure variables in our analysis sample was high.
The survey (CPES) responders were patients recently treated for cancer in NHS hospitals, a patient population with certain compositional differences compared with incident or prevalent cancer cases.
[23] These compositional differences arise from differences in survival in patient groups with different prognosis, both regarding patients with different cancers (e.g. resulting in a relative 'deficit' of responders with lung or pancreatic cancers, compared with a relative 'excess' of responders with breast cancer or melanoma) or between patient subgroups with the same cancer. Further, differential non-response (with men, younger and very old patients, more deprived, and ethnic minority patients being less likely to respond), and differential treatment patterns and duration also result in compositional differences between patient survey responders and other populations of cancer patients [23] . Relatedly, as patients diagnosed at advanced stages or through an emergency presentation had a higher risk of early mortality [24] , they were under-represented in patient surveys. While these considerations may suggest that our analyses have underestimated the overall prevalence of negative ratings of care, such differences are unlikely to have substantially biased the estimates of associations. Additionally, the fact that CPES responders consisted of a special population (cancer survivors with recent hospital treatment) needs to be borne in mind when interpreting the findings.
Given the public reporting conventions for this survey, we dichotomised the outcome (i.e. overall satisfaction with care) in our analysis. Future work may explore alternative parameterisations for analysing this item.
Comparisons with existing evidence
We were not aware of previous studies that characterise associations between reported patient experience of cancer care and both tumour stage at diagnosis and diagnostic route considered together. With regard to examining associations between cancer patient experience and tumour stage, a recent Dutch study assessed the level of satisfaction with hospital care among patients with advanced cancer and found no evidence for an association between a surrogate of stage (estimated life expectancy in months) and general satisfaction with care. [10] Similarly, a US study on ratings of quality of cancer care among a sample of lung and colorectal cancer patients indicated no association between tumour stage and overall ratings of cancer care in the adjusted analysis. [26] It is worth noting that the first of these studies had a very small sample size (N = 105) and that both studies adjusted for health status which is likely to mediate the effect of tumour stage at diagnosis.
With regard to examining associations between cancer patient experience and diagnostic route, a previous study [14] examined the impact of diagnostic route (without adjustment for stage at diagnosis) on reported experience of key aspects of cancer care (not including satisfaction with overall cancer care) among colorectal cancer patients who responded to the 2010 CPES; screen-detected patients were found to be associated with the best and emergency presenters the worst experience of cancer care. In addition, two recent Danish studies reported that cancer patients managed through 'fast-track' referrals (similar to the two-week-wait route) were less likely to be dissatisfied with the length of waiting times and more likely to be satisfied with their subsequent cancer care, compared with those referred electively. [27, 28] Our study cannot explain the reasons for the observed variation in care satisfaction by diagnostic route. The fact that emergency presenters were found to be the least satisfied with their care may reflect the negative psychological impact of being diagnosed in an emergency context. Similarly, electively referred patients may rate their care more negatively if they feel that their diagnosis could have been more timely had they been 'fast-tracked' through a two-week-wait referral, as perceived diagnostic delay is associated with distress. [29] These are plausible and intuitive hypotheses which should be examined empirically by further research. These previous studies however were not able to adjust for the likely influence of stage at diagnosis on the diagnostic pathways. In contrast, in our study we were able to examine the influence of both diagnostic route and stage at diagnosis, with the adjusted analysis indicating that both could be influencing care experience independently of each other.
Implications
The finding that emergency presenters and patients with the most advanced tumour stage were more likely to report a negative experience of overall cancer care highlights the need for service improvement targeting these groups of patients. There may be opportunities to improve the availability of services (e.g. in the context of emergency presentations) or the management of patients with advanced tumour stages, though how this can be achieved should be addressed in future research. Continued efforts to improve timely diagnosis of cancer and to reduce the number of emergency presenters will also likely lead to a reduction in the number of patients who are not satisfied with the quality of their care.
The results also suggest that after adjusting for tumour stage and diagnostic route, sociodemographic inequalities (by age, sex, and social deprivation) prevailed. Therefore, disease severity does not appear to fully explain these disparities. Whether these disparities reflected differential norms in expectations of care quality or actually worse care cannot be answered by our findings. Future empirical research, such as using standardised encounters (e.g. 'vignettes') may be helpful. [30] When cancer patient survey data are used for epidemiological research, potential compositional differences between the analysis sample (which represents recently treated cancer survivors) and other populations of prior interest (e.g. incident or prevalent cases) might limit the external validity of findings. Therefore, in addition to the variation in reported experience by patient characteristic and cancer site variables, [9] associations between diagnostic route, tumour stage at diagnosis, and reported experience need to be considered when applying methods for dealing with sample distortions, such as the inclusion of these variables in deriving post-stratification weights. [25] 
Conclusions
In conclusion, we report variation in experience of overall care among cancer patients with different tumour stages at diagnosis, diagnostic routes, and other characteristics. These associations need to be borne in mind when using patient experience survey data for epidemiological research. A reduction in the proportion of patients who are diagnosed with cancer as an emergency, greater availability and uptake of screening interventions, and reduction in the incidence of late-stage diseases may contribute to improvements in care experience. The findings could guide improvement efforts in the care of patients diagnosed via emergency presentation and those with advanced-stage disease, who are also higher-risk groups of reporting poorer experience of cancer care.
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